Asacol Copycats Must Use PK Data to Meet Bioequivalence Standards

Washington Drug Letter
The FDA has granted a Warner Chilcott citizen petition, agreeing not to approve generic versions of the company’s ulcerative colitis drug Asacol that do not meet bioequivalence standards using in vitro dissolution and comparative pharmacokinetic (PK) data.

To View This Article:


Buy This Article Now

Add this article to your cart for $25.00